I'll research WM (Waste Management) before writing the earnings preview. Let me gather recent data.Let me read the most recent earnings materials and check for analyst expectations.Let me get the full-year 2026 guidance and prior-year Q2 comp, plus recent stock price and news.Let me get the FY2026 guidance (from Q4 2025 release) and the prior-year Q2 2025 results for comps.I have what I need. Let me pull the latest stock levels into perspective and write the preview.Here is my earnings preview.


WM (Waste Management) — Q2 2026 Earnings Preview

Reports before market open Tuesday, July 28, 2026 (conference call 10:00 a.m. ET, July 29)

The one-line setup

WM heads into Q2 as a "show-me-the-harvest" story: after a two-year, multi-billion-dollar investment cycle in sustainability (RNG + recycling), fleet, and the Stericycle/Healthcare acquisition, 2026 is management's self-described "year of harvest." The core solid-waste machine remains exceptionally durable, but this print carries a tough year-over-year comp (last year's California wildfire cleanup volumes) and sets up the mid-year guidance refresh that investors most want to see.


1. Where the stock is


2. The comp problem: wildfires and volume optics

This is the single most important context for reading the headline. - Q2 2025 was inflated by ~$85M of Southern California wildfire cleanup revenue with high EBITDA flow-through. That does not repeat, creating a landfill/special-waste volume and margin headwind concentrated in Q2 (it largely anniversaries by August). - In Q1 2026, reported collection & disposal volume was -1.5%, but management stressed that ~half the shortfall was severe winter weather (10-day facility shutdowns on the East Coast). Underlying signals were better: MSW volume +2.7% (and reportedly ~4%+ in late April), special waste +6.7% ex-wildfire, and industrial/roll-off finally turning positive after ~6–7 negative quarters.

What to watch: Don't be spooked by an optically soft landfill/special-waste volume line — parse the ex-wildfire trend and the MSW/industrial trajectory. Management flagged these as leading indicators of underlying customer optimism. A clean beat on ex-wildfire special waste would be a strong macro tell.


3. Pricing and price/cost spread — the core margin engine

What to watch: Whether yield/core price stays above the guided range, and whether the spread holds despite the wildfire-driven loss of high-margin landfill volume.


4. Margins — mind the accretion reclassification

What to watch: Q2 2025 adjusted margin was 29.9%; on the new (accretion-excluded) basis plus underlying expansion, a print comfortably >31% would confirm the "structurally higher margin" narrative. Also watch corporate/other expense — Q1 was a deliberately heavy tech-investment/incentive-comp comp; management said that level is roughly the run-rate for the year.


5. Healthcare Solutions (Stericycle) — the inflection quarter?

This is the biggest swing factor on the story's credibility. - Q1 delivered ~12% adjusted EBITDA growth and +200 bps margin on SG&A synergies, despite revenue pressure from prior-year customer losses (only 1 of 3 expected hospital losses actually left). - Management explicitly guided to a revenue-growth inflection in 2H 2026 as the ERP stabilizes, customer credits reverse (DSO down 14 days, past-due receivables down two-thirds), and cross-selling ramps (~$27M annualized EBITDA benefit cited). - Synergy target of $300M run-rate by end-2027 is on track, with management hinting at possible upside to ~$325M.

What to watch: Early evidence of the promised revenue inflection (or at least stabilization), Healthcare margin (guided toward the ~17%+ adjusted zone and rising), and any raised synergy target. A miss here would dent the whole "accretive medical-waste platform" thesis.


6. Sustainability ramp — RNG and recycling

What to watch: Confirmation of the $240–250M sustainability EBITDA contribution, RNG plant commissioning timing (management flagged some utility interconnect delays), and updated commodity/RIN price assumptions.


7. Cash flow, capital returns, and the balance sheet

What to watch: Buyback pace (is the 2H weighting still intact?), any acquisition closings (management said a deal was imminent), and reaffirmation of the FCF trajectory.


8. Tax rate — a quiet EPS swing factor


9. The mid-year guidance refresh — the real event

On the Q1 call, Jim Fish deferred a guidance decision: "we'll really kind of take a refresh of our guidance numbers at the end of Q2." With pricing running ahead of plan, FCF strong, and volumes recovering, the bar is set for at least a narrowing toward the high end of the FY ranges: - Revenue $26,425–26,625M (+5.2%) - Adjusted EBITDA $8,150–8,250M (+6.2% comparable; margin 30.8–31.0%) - FCF $3,750–3,850M

A raise (especially on FCF/EBITDA) would validate the harvest thesis; a mere reaffirmation despite the Q1 pricing beat could disappoint a full valuation.


My rough Q2 2026 framework (model-derived, not consensus)

Backing Q1's $1,853M adjusted EBITDA out of the FY midpoint leaves ~$2,116M average per quarter for Q2–Q4. Q2 is seasonally strong but carries the wildfire comp, so I'd frame:

Metric Q2 2025 (comp) My Q2 2026 ballpark Notes
Revenue $6,430M ~$6,650–6,800M +3–5%; wildfire drag vs. price + sustainability
Adj. EBITDA $1,923M ~$2,040–2,100M +6–9%; margin ~31%+ on new basis
Adj. EBITDA margin 29.9% ~31.0–31.3% boosted by accretion reclass + spread
Adj. EPS $1.92 ~$2.02–2.10 higher tax rate a partial offset
FCF (H1 cum.) $1.29B ~$1.8–2.0B tracking toward big FY step-up

Bottom line — what makes or breaks the print

  1. Volume ex-wildfire (MSW/industrial acceleration) → the macro read and the 2H setup.
  2. Guidance refresh → narrow-to-high-end or raise is the key catalyst given a full valuation.
  3. Healthcare 2H revenue inflection proof points → the credibility swing factor.
  4. Margin on the new accretion basis holding >31% despite the wildfire comp.
  5. Sustainability EBITDA + RNG commissioning timing and capital-return cadence.

Risks skew toward "good quarter, but priced for it": the stock's YTD outperformance and elevated multiple mean the reaction likely hinges more on the guidance update and Healthcare/volume trajectory than on the headline EPS beat itself.

Note: figures above are drawn from WM's Q1 2026, Q4/FY2025, and Q2 2025 releases and the Q1 2026 call; the Q2 2026 table is my own estimate, not published company guidance or sell-side consensus.